Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2186899,maximum concentration (Cmax),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],285,748,DB01131,Proguanil
,2186899,maximum concentration (Cmax),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],151,749,DB01131,Proguanil
,2186899,minimum concentration (Cmin),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],125,750,DB01131,Proguanil
,2186899,minimum concentration (Cmin),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],31,751,DB01131,Proguanil
,2186899,elimination half-life (t1/2),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,23.3,752,DB01131,Proguanil
,2186899,elimination half-life (t1/2),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,18.3,753,DB01131,Proguanil
,2186899,plasma clearance (Cl),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [h·kg],0.032,754,DB01131,Proguanil
,2186899,plasma clearance (Cl),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [h·kg],1.27,755,DB01131,Proguanil
,2186899,apparent volume of distribution (Vss),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [kg],1.05,756,DB01131,Proguanil
,2186899,apparent volume of distribution (Vss),"The following kinetic parameters (mean values) were estimated for DDS and PROG, respectively: maximum concentration (Cmax) = 285 and 151 ng/ml, minimum concentration (Cmin) = 125 and 31 ng/ml, elimination half-life (t1/2) = 23.3 and 18.3 h, plasma clearance (Cl) = 0.032 and 1.27 l/h/kg and apparent volume of distribution (Vss) = 1.05 and 33.32 l/kg.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[l] / [kg],33.32,757,DB01131,Proguanil
,2186899,Cmax,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],56,758,DB01131,Proguanil
,2186899,Cmin,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),[ng] / [ml],17,759,DB01131,Proguanil
,2186899,t1/2,"The Cmax, Cmin and t1/2 of CYCLO were 56 ng/ml, 17 ng/ml and 15.0 h, respectively.",Multiple-dose kinetics in healthy volunteers and in vitro antimalarial activity of proguanil plus dapsone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186899/),h,15.0,760,DB01131,Proguanil
,23264940,flow rate,"The reconstituted samples were chromatographed on a Zorbax XDB Phenyl column by using a mixture of 0.2% acetic acid buffer, methanol, and acetonitrile (20:16:64, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),[ml] / [min],0.8,5160,DB01131,Proguanil
,23264940,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),min,3.0,5161,DB01131,Proguanil
,16041597,Cmax,"For atovaquone, a Cmax of 1.33-8.33 microg/ml was reached at 2.0-9.3 h after the last dose on day 2.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[μg] / [ml],1.33-8.33,17797,DB01131,Proguanil
,16041597,V/F,"V/F, CL/F and t(1/2beta) were 6.9-39.5 l/kg, 83-384 ml/h/kg, and 57.8-130.8 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[l] / [kg],6.9-39.5,17798,DB01131,Proguanil
,16041597,CL/F,"V/F, CL/F and t(1/2beta) were 6.9-39.5 l/kg, 83-384 ml/h/kg, and 57.8-130.8 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],83-384,17799,DB01131,Proguanil
,16041597,t(1/2beta),"V/F, CL/F and t(1/2beta) were 6.9-39.5 l/kg, 83-384 ml/h/kg, and 57.8-130.8 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,57.8-130.8,17800,DB01131,Proguanil
,16041597,Cmax,"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ng] / [ml],383-918,17801,DB01131,Proguanil
,16041597,t(max),"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ng] / [ml],0-129,17802,DB01131,Proguanil
,16041597,t(max),"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,3.3-8.6,17803,DB01131,Proguanil
,16041597,t(max),"The Cmax and t(max) values for proguanil versus cycloguanil were 383-918 versus 0-129 ng/ml and 3.3-8.6 versus 3-12 h, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,3-12,17804,DB01131,Proguanil
,16041597,V/F,"V/F, CL/F, and t(1/2beta) values for proguanil were 10.7-34.0 l/kg, 431-1,662 ml/h/kg and 11.2-30.3 h.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[l] / [kg],10.7-34.0,17805,DB01131,Proguanil
,16041597,CL/F,"V/F, CL/F, and t(1/2beta) values for proguanil were 10.7-34.0 l/kg, 431-1,662 ml/h/kg and 11.2-30.3 h.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],"431-1,662",17806,DB01131,Proguanil
,16041597,t(1/2beta),"V/F, CL/F, and t(1/2beta) values for proguanil were 10.7-34.0 l/kg, 431-1,662 ml/h/kg and 11.2-30.3 h.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,11.2-30.3,17807,DB01131,Proguanil
,16041597,CL(R-CG),"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],"107.2-1,001",17808,DB01131,Proguanil
,16041597,t(1/2z),"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],5-95,17809,DB01131,Proguanil
,16041597,t(1/2z),"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,7.8-20.7,17810,DB01131,Proguanil
,16041597,metabolic ratios,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],5-95,17811,DB01131,Proguanil
,16041597,metabolic ratios,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,7.8-20.7,17812,DB01131,Proguanil
,16041597,AUC(,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),[ml] / [h·kg],5-95,17813,DB01131,Proguanil
,16041597,AUC(,"The CL(R-CG), t(1/2z), (CG), proguanil/cycloguanil metabolic ratios, AUC ratios for proguanil to cycloguanil (AUC(PG/CG)) were 107.2-1,001 ml/h/kg, 5-95 ml/h/kg, 7.8-20.7 h, 5-57, and 4.7-20.2, respectively.",The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16041597/),h,7.8-20.7,17814,DB01131,Proguanil
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,1.68,19503,DB01131,Proguanil
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,1.38,19504,DB01131,Proguanil
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,4.78,19505,DB01131,Proguanil
,23385314,K(i),The present study showed that efavirenz was a potent competitive inhibitor of CYP2B6 (average K(i) = 1.68 µM in HLMs and K(i) = 1.38 µM in expressed CYP2B6) and CYP2C8 (K(i) = 4.78 µM in pooled HLMs and K(i) = 4.80 µM in HLMs with CYP2C8*3/*3 genotype).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,4.80,19506,DB01131,Proguanil
,23385314,K(i),Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 µM) and CYP2C19 (K(i) = 21.31 µM); and a weak inhibitor of CYP3A (K(i) = 40.33 µM).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,19.46,19507,DB01131,Proguanil
,23385314,K(i),Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 µM) and CYP2C19 (K(i) = 21.31 µM); and a weak inhibitor of CYP3A (K(i) = 40.33 µM).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,21.31,19508,DB01131,Proguanil
,23385314,K(i),Efavirenz was a moderate inhibitor of CYP2C9 (K(i) = 19.46 µM) and CYP2C19 (K(i) = 21.31 µM); and a weak inhibitor of CYP3A (K(i) = 40.33 µM).,"In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23385314/),μM,40.33,19509,DB01131,Proguanil
,12955371,oral clearance (Cl/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[ml] / [h·kg],313,27954,DB01131,Proguanil
,12955371,oral clearance (Cl/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[ml] / [h·kg],1109,27955,DB01131,Proguanil
,12955371,total apparent volume of distribution (Vd/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[l] / [kg],13.0,27956,DB01131,Proguanil
,12955371,total apparent volume of distribution (Vd/F),"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),[l] / [kg],22.9,27957,DB01131,Proguanil
,12955371,terminal elimination half-life,"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),h,29.1,27958,DB01131,Proguanil
,12955371,terminal elimination half-life,"Population mean (+/- SEM) oral clearance (Cl/F) estimates were 313+/-33 ml/h/kg and 1109+/-43 ml/h/kg, total apparent volume of distribution (Vd/F) 13.0+/-1.3 l/kg and 22.9+/-1.4 l/kg, and terminal elimination half-life; 29.1 h and 14.3 h, for atovaquone and proguanil, respectively.",The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12955371/),h,14.3,27959,DB01131,Proguanil
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],3,36204,DB01131,Proguanil
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],1,36205,DB01131,Proguanil
,8619446,detection limits,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],5,36206,DB01131,Proguanil
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],3,36207,DB01131,Proguanil
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],1,36208,DB01131,Proguanil
,8619446,signal-to-noise ratio,"The detection limits of PG, CG, and CPB, defined as the signal-to-noise ratio of 3, were 1 and 5 ng/ml for plasma and urine samples, respectively.","Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),[ng] / [ml],5,36209,DB01131,Proguanil
>,8619446,Recoveries,Recoveries of the analytes and the internal standard (pyrimethamine) were > 62% from plasma and > 77% from urine.,"Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),%,62,36210,DB01131,Proguanil
>,8619446,Recoveries,Recoveries of the analytes and the internal standard (pyrimethamine) were > 62% from plasma and > 77% from urine.,"Simultaneous measurement of proguanil and its metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography, and its preliminary application in relation to genetically determined S-mephenytoin 4'-hydroxylation status. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8619446/),%,77,36211,DB01131,Proguanil
,3180907,maximum plasma proguanil concentration,A maximum plasma proguanil concentration of 130.3 +/- 16.0 ng/ml (mean +/- SD) was reached at 3.8 +/- 1.3 h while a maximum cycloguanil concentration of 52.0 +/- 15.2 ng/ml was obtained at 5.3 +/- 1.0 h after dosing.,"Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180907/),[ng] / [ml],130.3,39580,DB01131,Proguanil
,3180907,maximum cycloguanil concentration,A maximum plasma proguanil concentration of 130.3 +/- 16.0 ng/ml (mean +/- SD) was reached at 3.8 +/- 1.3 h while a maximum cycloguanil concentration of 52.0 +/- 15.2 ng/ml was obtained at 5.3 +/- 1.0 h after dosing.,"Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180907/),[ng] / [ml],52.0,39581,DB01131,Proguanil
,3180907,elimination half-lives,"The elimination half-lives of proguanil and cycloguanil were 14.5 +/- 3.0 h and 11.7 +/- 3.1 h, respectively.","Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180907/),h,14.5,39582,DB01131,Proguanil
,3180907,elimination half-lives,"The elimination half-lives of proguanil and cycloguanil were 14.5 +/- 3.0 h and 11.7 +/- 3.1 h, respectively.","Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180907/),h,11.7,39583,DB01131,Proguanil
,3180907,plasma clearance,The plasma clearance of proguanil was 1.43 +/- 0.33 l/h/kg and the apparent volume of distribution was 30.7 +/- 12.3 l/kg.,"Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180907/),[l] / [h·kg],1.43,39584,DB01131,Proguanil
,3180907,apparent volume of distribution,The plasma clearance of proguanil was 1.43 +/- 0.33 l/h/kg and the apparent volume of distribution was 30.7 +/- 12.3 l/kg.,"Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180907/),[l] / [kg],30.7,39585,DB01131,Proguanil
,3180907,Renal clearance,Renal clearance of proguanil (0.33 +/- 0.19 l/h/kg) was about 23% of the plasma clearance and 35.6 +/- 9.6% of the oral dose was recovered as proguanil and cycloguanil.,"Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3180907/),[l] / [h·kg],0.33,39586,DB01131,Proguanil
,3445299,detection limit,The detection limit in plasma and urine was 5 ng/ml for chlorproguanil and 10 ng/ml for chlorcycloguanil.,Chlorproguanil and chlorcycloguanil concentrations in human plasma and urine after Lapudrine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3445299/),[ng] / [ml],5,52354,DB01131,Proguanil
,3445299,detection limit,The detection limit in plasma and urine was 5 ng/ml for chlorproguanil and 10 ng/ml for chlorcycloguanil.,Chlorproguanil and chlorcycloguanil concentrations in human plasma and urine after Lapudrine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3445299/),[ng] / [ml],10,52355,DB01131,Proguanil
,3445299,elimination half-life,"The elimination half-life of chlorproguanil (Lapudrine) in 2 healthy volunteers, after a single oral dose of the drug, was 14.7 and 16.1 h.",Chlorproguanil and chlorcycloguanil concentrations in human plasma and urine after Lapudrine administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3445299/),h,14.7,52356,DB01131,Proguanil
,3445299,elimination half-life,"The elimination half-life of chlorproguanil (Lapudrine) in 2 healthy volunteers, after a single oral dose of the drug, was 14.7 and 16.1 h.",Chlorproguanil and chlorcycloguanil concentrations in human plasma and urine after Lapudrine administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3445299/),h,16.1,52357,DB01131,Proguanil
,3037875,terminal phase elimination half life,"The drug was rapidly absorbed reaching a peak concentration in the blood within 3 h, and declining slowly thereafter to give a terminal phase elimination half life of 11.20 +/- 4.10 h and a systemic clearance of 1.270 +/- 0.020 l/h/kg.",The pharmacokinetics of proguanil in human subjects following a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3037875/),h,11.20,55302,DB01131,Proguanil
,3037875,systemic clearance,"The drug was rapidly absorbed reaching a peak concentration in the blood within 3 h, and declining slowly thereafter to give a terminal phase elimination half life of 11.20 +/- 4.10 h and a systemic clearance of 1.270 +/- 0.020 l/h/kg.",The pharmacokinetics of proguanil in human subjects following a single oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3037875/),[l] / [h·kg],1.270,55303,DB01131,Proguanil
,11956669,AUC(0-tau),"Four volunteers, with mean CYCLO/PROG AUC(0-tau) of 0.03 (-0.23, 0.09) were classified as poor metaboliser (PM) phenotypes.",Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956669/),,0.03,57414,DB01131,Proguanil
,11956669,AUC(0-tau)/AUC(0-infinity) ratio,"There was a significant increase in the AUC of PROG at steady state with a PROG AUC(0-tau)/AUC(0-infinity) ratio of 1.38 (1.07, 1.69) in extensive metaboliser (EM) phenotypes.",Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956669/),,1.38,57415,DB01131,Proguanil
,11956669,AUC ratios,"CYCLO/PROG AUC ratios were significantly lower 0.67 (0.54, 0.81) at steady state than that after the first single dose in EM phenotypes.",Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11956669/),,0.67,57416,DB01131,Proguanil
,16487222,ka,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),1/[h],00.09,64657,DB01131,Proguanil
,16487222,CL/F,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),[l] / [h],51.53,64658,DB01131,Proguanil
,16487222,CLD/F,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),[l] / [h],54.67,64659,DB01131,Proguanil
,16487222,V1/F,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),l,234.40,64660,DB01131,Proguanil
,16487222,V2/F,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),l,1612.75,64661,DB01131,Proguanil
,16487222,ka,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),1/[h],00.93,64662,DB01131,Proguanil
,16487222,CL/F,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),[l] / [h],1.99,64663,DB01131,Proguanil
,16487222,V/F,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),l,76.96,64664,DB01131,Proguanil
,16487222,CLm/Fm,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),[l] / [h·kg],3.72,64665,DB01131,Proguanil
,16487222,Vm/Fm,"The population pharmacokinetic parameter estimates for chlorproguanil were ka=00.09 h-1 (intersubject variability was 44%), CL/F=51.53 l h-1 (57%), CLD/F=54.67 l h-1, V1/F=234.40 l (50%) and V2/F=1612.75 l; for dapsone were ka=00.93 h-1, CL/F=1.99 l h-1 (72%) and V/F=76.96 l (48%); and for chlorcycloguanil were CLm/Fm=3.72 l h-1 kg-1 (67%) and Vm/Fm=12.76 l kg-1 (64%).",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),[l] / [kg],12.76,64666,DB01131,Proguanil
,16487222,duration,"For a 10-kg child, the mean duration of parasitocidal activity for chlorproguanil/dapsone against the three most susceptible P. falciparum strains was 4.5 days [5th and 95th percentiles 2.4, 7.3] for W282; 5.9 days (3.6, 9.7) for ItG2F6; and 6.1 days (3.7, 10.1) for K39.",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),d,4.5,64667,DB01131,Proguanil
,16487222,duration,"For a 10-kg child, the mean duration of parasitocidal activity for chlorproguanil/dapsone against the three most susceptible P. falciparum strains was 4.5 days [5th and 95th percentiles 2.4, 7.3] for W282; 5.9 days (3.6, 9.7) for ItG2F6; and 6.1 days (3.7, 10.1) for K39.",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),d,5.9,64668,DB01131,Proguanil
,16487222,duration,"For a 10-kg child, the mean duration of parasitocidal activity for chlorproguanil/dapsone against the three most susceptible P. falciparum strains was 4.5 days [5th and 95th percentiles 2.4, 7.3] for W282; 5.9 days (3.6, 9.7) for ItG2F6; and 6.1 days (3.7, 10.1) for K39.",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),d,6.1,64669,DB01131,Proguanil
,16487222,"V1/S, activity","For an isolate with the ile-164-leu mutation, V1/S, activity ranged from 0.8 days (0.0, 3.3) for a 10-kg child to 1.8 days (0.0, 4.0) for a 60-kg adult.",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),d,0.8,64670,DB01131,Proguanil
,16487222,"V1/S, activity","For an isolate with the ile-164-leu mutation, V1/S, activity ranged from 0.8 days (0.0, 3.3) for a 10-kg child to 1.8 days (0.0, 4.0) for a 60-kg adult.",Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16487222/),d,1.8,64671,DB01131,Proguanil
,2576454,tmax,"The tmax and elimination half-life of proguanil derived from salivary levels were 4.0 +/- 1.26 h and 15.1 +/- 1.8 h, respectively.",Excretion of proguanil in human saliva. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576454/),h,4.0,69807,DB01131,Proguanil
,2576454,elimination half-life,"The tmax and elimination half-life of proguanil derived from salivary levels were 4.0 +/- 1.26 h and 15.1 +/- 1.8 h, respectively.",Excretion of proguanil in human saliva. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576454/),h,15.1,69808,DB01131,Proguanil
,2576454,saliva: plasma proguanil,The mean saliva: plasma proguanil concentration ratio was 0.41 +/- 0.17 and this was not time dependent.,Excretion of proguanil in human saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576454/),,0.41,69809,DB01131,Proguanil
,2576454,concentration ratio,The mean saliva: plasma proguanil concentration ratio was 0.41 +/- 0.17 and this was not time dependent.,Excretion of proguanil in human saliva. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576454/),,0.41,69810,DB01131,Proguanil
,3208546,maximum plasma chlorproguanil concentration,The mean maximum plasma chlorproguanil concentration was 36.7 +/- (SD) 7.9 ng/ml and was reached at 3.8 +/- 1.3 h.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),[ng] / [ml],36.7,76147,DB01131,Proguanil
,3208546,elimination half-life,The chlorproguanil elimination half-life was 17.5 +/- 6.7 h and its plasma clearance was 1.28 +/- 0.12 l/h/kg.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),h,17.5,76148,DB01131,Proguanil
,3208546,plasma clearance,The chlorproguanil elimination half-life was 17.5 +/- 6.7 h and its plasma clearance was 1.28 +/- 0.12 l/h/kg.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),[l] / [h·kg],1.28,76149,DB01131,Proguanil
,3208546,whole blood to plasma ratio,The mean whole blood to plasma ratio was 3.1 at 4 h after dosing.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),,3.1,76150,DB01131,Proguanil
,3208546,t1/2,An excretion rate-time plot from urine data shows a rapid (t1/2 = 20 h) and a slow phase (t1/2 = 51 h) in the elimination of chlorcycloguanil.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),h,20,76151,DB01131,Proguanil
,3208546,t1/2,An excretion rate-time plot from urine data shows a rapid (t1/2 = 20 h) and a slow phase (t1/2 = 51 h) in the elimination of chlorcycloguanil.,Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208546/),h,51,76152,DB01131,Proguanil
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],3.28,80932,DB01131,Proguanil
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],8.49,80933,DB01131,Proguanil
,9164414,CL/F,"On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),[l] / [h],9.13,80934,DB01131,Proguanil
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,345,80935,DB01131,Proguanil
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,383,80936,DB01131,Proguanil
,9164414,V area/F,"The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),l,428,80937,DB01131,Proguanil
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,72.9,80938,DB01131,Proguanil
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,31.3,80939,DB01131,Proguanil
,9164414,t1/2,"Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively.",Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164414/),h,32.5,80940,DB01131,Proguanil
,22052893,area under the curve,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [d·ml],423,81603,DB01131,Proguanil
,22052893,area under the curve,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [d·ml],199,81604,DB01131,Proguanil
,22052893,area under the curve,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [d·ml],1903,81605,DB01131,Proguanil
,22052893,peak concentration,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [ml],165,81606,DB01131,Proguanil
,22052893,peak concentration,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [ml],81,81607,DB01131,Proguanil
,22052893,peak concentration,"Atovaquone exposure (area under the curve) during liver stage development was low in 2 of 3 volunteers with prophylactic failure (423 and 199 ng/mL × days compared with a mean for protected volunteers of 1903 ng/mL × days), as was peak concentration (165 and 81 ng/mL compared with a mean of 594 ng/mL in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),[ng] / [ml],594,81608,DB01131,Proguanil
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,2.4,81609,DB01131,Proguanil
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,2.0,81610,DB01131,Proguanil
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,3.3,81611,DB01131,Proguanil
,22052893,Elimination half-life,"Elimination half-life was short in volunteers with prophylactic failure (2.4, 2.0, and 3.3 days compared with a mean of 4.1 days in volunteers with prophylactic success).",Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22052893/),d,4.1,81612,DB01131,Proguanil
,9279980,CL/F,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),[l] / [h·kg],1.25,98935,DB01131,Proguanil
,9279980,CL/F,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),[l] / [h·kg],0.95,98936,DB01131,Proguanil
,9279980,t1/2,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),h,14.2,98937,DB01131,Proguanil
,9279980,t1/2,"The median (range) kinetic values of PROG in patients given PROG alone and PROG/ATQ were respectively: CL/F = 1.25 l/h/kg (0.99-1.45) and 0.95 (0.73-1.32) l/h/kg, and t1/2 = 14.2 hours (9.3-16.8) and 13.6 hours (9.1-17.6).",Pharmacokinetics of proguanil in malaria patients treated with proguanil plus atovaquone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9279980/),h,13.6,98938,DB01131,Proguanil
,7654492,Volume of distribution,"Volume of distribution, elimination half-life and clearance were not different for the three regimens, ranging from 250-302 l kg-1, 374-479 h and 0.44-0.58 l h-1 kg-1 respectively.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[l] / [kg],250-302,106188,DB01131,Proguanil
,7654492,elimination half-life,"Volume of distribution, elimination half-life and clearance were not different for the three regimens, ranging from 250-302 l kg-1, 374-479 h and 0.44-0.58 l h-1 kg-1 respectively.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),h,374-479,106189,DB01131,Proguanil
,7654492,clearance,"Volume of distribution, elimination half-life and clearance were not different for the three regimens, ranging from 250-302 l kg-1, 374-479 h and 0.44-0.58 l h-1 kg-1 respectively.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[l] / [h·kg],0.44-0.58,106190,DB01131,Proguanil
above,7654492,peak,"After the first week of all dosage regimens, peak and trough concentrations of chloroquine were above 16 micrograms l-1, sufficiently suppressive for chloroquine-sensitive P. falciparum strains.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[μg] / [l],16,106191,DB01131,Proguanil
above,7654492,trough concentrations,"After the first week of all dosage regimens, peak and trough concentrations of chloroquine were above 16 micrograms l-1, sufficiently suppressive for chloroquine-sensitive P. falciparum strains.",The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654492/),[μg] / [l],16,106192,DB01131,Proguanil
,3440097,time to peak plasma concentration,2. Proguanil was absorbed with a median time to peak plasma concentration of 3 h (range 2-4 h).,Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),h,3,111603,DB01131,Proguanil
,3440097,Peak plasma concentrations,"3. Peak plasma concentrations of proguanil ranged between 150 and 220 (median 170) ng ml-1 compared with 12 to 69 (median 41) ng ml-1 for the active antimalarial metabolite CG, and 3 to 16 (median 11) ng ml-1 for CPB.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),[ng] / [ml],150 and 220,111604,DB01131,Proguanil
,3440097,Peak plasma concentrations,"3. Peak plasma concentrations of proguanil ranged between 150 and 220 (median 170) ng ml-1 compared with 12 to 69 (median 41) ng ml-1 for the active antimalarial metabolite CG, and 3 to 16 (median 11) ng ml-1 for CPB.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),[ng] / [ml],12 to 69,111605,DB01131,Proguanil
,3440097,Peak plasma concentrations,"3. Peak plasma concentrations of proguanil ranged between 150 and 220 (median 170) ng ml-1 compared with 12 to 69 (median 41) ng ml-1 for the active antimalarial metabolite CG, and 3 to 16 (median 11) ng ml-1 for CPB.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),[ng] / [ml],3 to 16,111606,DB01131,Proguanil
,3440097,AUC,"5. A triexponential function was fitted to these data; mean (+/- s.d.) values for the AUC were 3046 +/- 313 ng ml-1 h for proguanil, 679 +/- 372 ng ml-1 h for CG and 257 +/- 155 ng ml-1 h for CPB.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),[h·ng] / [ml],3046,111607,DB01131,Proguanil
,3440097,AUC,"5. A triexponential function was fitted to these data; mean (+/- s.d.) values for the AUC were 3046 +/- 313 ng ml-1 h for proguanil, 679 +/- 372 ng ml-1 h for CG and 257 +/- 155 ng ml-1 h for CPB.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),[h·ng] / [ml],679,111608,DB01131,Proguanil
,3440097,AUC,"5. A triexponential function was fitted to these data; mean (+/- s.d.) values for the AUC were 3046 +/- 313 ng ml-1 h for proguanil, 679 +/- 372 ng ml-1 h for CG and 257 +/- 155 ng ml-1 h for CPB.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),[h·ng] / [ml],257,111609,DB01131,Proguanil
,3440097,terminal elimination half-lives,"6. Plasma and whole blood concentrations of proguanil and its metabolites declined in parallel with terminal elimination half-lives estimated as 16.1 +/- 2.9 h and 15.7 +/- 2.4 h, respectively.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),h,16.1,111610,DB01131,Proguanil
,3440097,terminal elimination half-lives,"6. Plasma and whole blood concentrations of proguanil and its metabolites declined in parallel with terminal elimination half-lives estimated as 16.1 +/- 2.9 h and 15.7 +/- 2.4 h, respectively.",Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),h,15.7,111611,DB01131,Proguanil
,3440097,Mean residence times,Mean residence times in plasma and whole blood were estimated as 21.2 +/- 4.9 and 19.3 +/- 2.4 h.,Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),h,21.2,111612,DB01131,Proguanil
,3440097,Mean residence times,Mean residence times in plasma and whole blood were estimated as 21.2 +/- 4.9 and 19.3 +/- 2.4 h.,Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440097/),h,19.3,111613,DB01131,Proguanil
,8951190,CLo,"According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively.",Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951190/),[l] / [h],54.0,113316,DB01131,Proguanil
,8951190,CLo,"According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively.",Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951190/),[l] / [h],61.5,113317,DB01131,Proguanil
,8951190,CLo,"According to the mean weight of each population, the final population estimates of CLo in Blacks, Orientals and Malays who are 'extensive' metabolizers were 54.0, 61.5 and 64.3 l h-1, respectively.",Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8951190/),[l] / [h],64.3,113318,DB01131,Proguanil
,2255843,steady state mean peak concentration,"The steady state mean peak concentration of proguanil was 1201.6 +/- 132.4 nmol/l, the mean trough concentration 650.0 +/- 58.1 nmol/l.",Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255843/),[nM] / [l],1201.6,114860,DB01131,Proguanil
,2255843,trough concentration,"The steady state mean peak concentration of proguanil was 1201.6 +/- 132.4 nmol/l, the mean trough concentration 650.0 +/- 58.1 nmol/l.",Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255843/),[nM] / [l],650.0,114861,DB01131,Proguanil
,2255843,peak,The corresponding values for cycloguanil were 317.0 +/- 44.4 nmol/l (mean peak) and 230.8 +/- 35.1 nmol/l (mean trough).,Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255843/),[nM] / [l],317.0,114862,DB01131,Proguanil
,2255843,trough,The corresponding values for cycloguanil were 317.0 +/- 44.4 nmol/l (mean peak) and 230.8 +/- 35.1 nmol/l (mean trough).,Multiple-dose pharmacokinetic study of proguanil and cycloguanil following 12-hourly administration of 100 mg proguanil hydrochloride. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255843/),[nM] / [l],230.8,114863,DB01131,Proguanil
,19517101,AUC(0-infinity),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[h·ng] / [ml],64.6,117431,DB01131,Proguanil
,19517101,AUC(0-infinity),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[h·ng] / [ml],151,117432,DB01131,Proguanil
,19517101,AUC(0-infinity),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[h·ng] / [ml],400,117433,DB01131,Proguanil
,19517101,C(max),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[ng] / [ml],48.9,117434,DB01131,Proguanil
,19517101,C(max),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[ng] / [ml],106,117435,DB01131,Proguanil
,19517101,C(max),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[ng] / [ml],224,117436,DB01131,Proguanil
,19517101,AUC(0-infinity),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[h·ng] / [ml],538,117437,DB01131,Proguanil
,19517101,AUC(0-infinity),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[h·ng] / [ml],"1,445",117438,DB01131,Proguanil
,19517101,AUC(0-infinity),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[h·ng] / [ml],"3,837",117439,DB01131,Proguanil
,19517101,C(max),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[ng] / [ml],228,117440,DB01131,Proguanil
,19517101,C(max),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[ng] / [ml],581,117441,DB01131,Proguanil
,19517101,C(max),"For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC(0-infinity) was 64.6, 151 and 400 ng.h/ml and C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC(0-infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and 1,414 ng/ml respectively.","Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19517101/),[ng] / [ml],"1,414",117442,DB01131,Proguanil
,10613613,urinary metabolic ratio,Dextromethorphan urinary metabolic ratio increased from -2.52 +/- 0.67 to -2.03 +/- 0.58 (P < .001) in the presence of chloroguanide.,Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613613/),,2.52,117511,DB01131,Proguanil
,10613613,urinary metabolic ratio,Dextromethorphan urinary metabolic ratio increased from -2.52 +/- 0.67 to -2.03 +/- 0.58 (P < .001) in the presence of chloroguanide.,Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613613/),,2.03,117512,DB01131,Proguanil
,3629140,peak plasma concentrations,"In four subjects peak plasma concentrations of proguanil (500 to 600 nmol/l) were reached after two to three hours, while cycloguanil and p-chlorophenylbiguanide showed a plateau after three and six hours, respectively.",Human pharmacokinetics of proguanil and its metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3629140/),[nM] / [l],500 to 600,126155,DB01131,Proguanil
,3629140,Trough concentrations,"Trough concentrations (pre-dose in the morning) of proguanil and cycloguanil were about 200 and 100 nmol/l, respectively.",Human pharmacokinetics of proguanil and its metabolites. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3629140/),[nM] / [l],200,126156,DB01131,Proguanil
,3629140,Trough concentrations,"Trough concentrations (pre-dose in the morning) of proguanil and cycloguanil were about 200 and 100 nmol/l, respectively.",Human pharmacokinetics of proguanil and its metabolites. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3629140/),[nM] / [l],100,126157,DB01131,Proguanil
,3629140,half-life,Mean half-life of proguanil was estimated to approximately 20 h.,Human pharmacokinetics of proguanil and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3629140/),h,20,126158,DB01131,Proguanil
,9231209,maximum unbound chlorcycloguanil concentration,"After the first dose of chlorproguanil/dapsone the maximum unbound chlorcycloguanil concentration in clinical samples (19 ng/mL [about 60 nM]) was 2 orders of magnitude above the 50% inhibitory concentration (IC50) value for this drug against the K39 stain of P. falciparum, while falling 2 orders of magnitude below its IC50 against human bone marrow cells; the maximum unbound dapsone concentration in clinical samples (160 ng/mL [about 645 nM]) was 10-fold higher than its IC50 against the K39 strain.",Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231209/),[ng] / [ml],19,127893,DB01131,Proguanil
,9231209,maximum unbound dapsone concentration,"After the first dose of chlorproguanil/dapsone the maximum unbound chlorcycloguanil concentration in clinical samples (19 ng/mL [about 60 nM]) was 2 orders of magnitude above the 50% inhibitory concentration (IC50) value for this drug against the K39 stain of P. falciparum, while falling 2 orders of magnitude below its IC50 against human bone marrow cells; the maximum unbound dapsone concentration in clinical samples (160 ng/mL [about 645 nM]) was 10-fold higher than its IC50 against the K39 strain.",Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231209/),[ng] / [ml],160,127894,DB01131,Proguanil
,9231209,half-life,"However, because of the rapid elimination of chlorproguanil from the body (half-life 12.6 +/- 6.3 h), the minimum fractional inhibitory concentrations of unbound chlorcycloguanil/dapsone against the K39 strain were probably exceeded for no more than 6 d.",Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231209/),h,12.6,127895,DB01131,Proguanil
,3893840,half-lives (t1/2 beta),"In healthy subjects, the cinchona alkaloids (quinine and quinidine), primaquine and proguanil (chloroguanide) are all rapidly eliminated with half-lives (t1/2 beta) of between 6 and 12 hours.",Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,6 and 12,134980,DB01131,Proguanil
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6 to 50,134981,DB01131,Proguanil
,3893840,t1/2 beta,Chloroquine (t1/2 beta 6 to 50 days) and mefloquine (t1/2 beta 6.5 to 33 days) have extensive tissue distribution and prolonged activity after a single dose.,Clinical pharmacokinetics of antimalarial drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),d,6.5 to 33,134982,DB01131,Proguanil
,3893840,t1/2,"Pyrimethamine (t1/2 35 to 175 hours) has more limited tissue distribution, plasma and erythrocyte concentrations are similar, and 85% of the drug in plasma is bound to plasma proteins.",Clinical pharmacokinetics of antimalarial drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3893840/),h,35 to 175,134983,DB01131,Proguanil
,8866915,urinary recovery,4. The urinary recovery of PG ranged from 30 to 69% of the dose and for CG from 2.8 to 32% of the dose.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),%,30 to 69,137684,DB01131,Proguanil
,8866915,urinary recovery,4. The urinary recovery of PG ranged from 30 to 69% of the dose and for CG from 2.8 to 32% of the dose.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),%,2.8 to 32,137685,DB01131,Proguanil
,8866915,overall urinary recovery,The overall urinary recovery of PG plus CG ranged from 54 to 77% of the dose.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),%,54 to 77,137686,DB01131,Proguanil
,8866915,AUC,The AUC for PG ranged from 3.2 to 9.5 mg l-1 h whereas for CG it was from 0.02 to 0.71 mg l-1 h.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),[h·mg] / [l],3.2 to 9.5,137687,DB01131,Proguanil
,8866915,AUC,The AUC for PG ranged from 3.2 to 9.5 mg l-1 h whereas for CG it was from 0.02 to 0.71 mg l-1 h.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),[h·mg] / [l],0.02 to 0.71,137688,DB01131,Proguanil
,8866915,partial intrinsic clearance,The partial intrinsic clearance to CG ranged 25-fold from 0.41 to 10.1 l h-1.,Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866915/),[l] / [h],0.41 to 10.1,137689,DB01131,Proguanil
,9333103,total clearance,"During fluvoxamine use, the median of the total clearance of chloroguanide decreased in a statistically significant way from 1282 ml/min to 782 ml/min among the extensive metabolizers, whereas there was no change among the poor metabolizers.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],1282,142096,DB01131,Proguanil
,9333103,total clearance,"During fluvoxamine use, the median of the total clearance of chloroguanide decreased in a statistically significant way from 1282 ml/min to 782 ml/min among the extensive metabolizers, whereas there was no change among the poor metabolizers.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],782,142097,DB01131,Proguanil
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],222,142098,DB01131,Proguanil
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],97,142099,DB01131,Proguanil
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],33,142100,DB01131,Proguanil
,9333103,partial clearance,"The partial clearance of chloroguanide by means of cydoguanil and 4-chlorphenylbiguanide formation among the extensive metabolizers decreased from 222 ml/min and 97 ml/min before to 33 ml/min and 11 ml/min during fluvoxamine intake, respectively.",Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333103/),[ml] / [min],11,142101,DB01131,Proguanil
,2051526,t1/2,"The urinary recovery was about 45% of the dose and t1/2 31-44 h, both higher than previously reported.","Plasma, erythrocyte and urine concentrations of chlorproguanil and two metabolites in man after different doses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051526/),h,31-44,144675,DB01131,Proguanil
,2051526,apparent clearance,"The apparent clearance was 0.52-0.82 l h-1 kg-1, which is lower than previously found.","Plasma, erythrocyte and urine concentrations of chlorproguanil and two metabolites in man after different doses. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051526/),[l] / [h·kg],0.52-0.82,144676,DB01131,Proguanil
,2291871,oral clearance,"2. Pharmacokinetic analysis showed that this observation resulted from a reduced oral clearance of proguanil in these individuals (245, 534 and 552 ml min-1) compared with the rest of the population (858 +/- 482 ml min-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ml] / [min],245,146243,DB01131,Proguanil
,2291871,oral clearance,"2. Pharmacokinetic analysis showed that this observation resulted from a reduced oral clearance of proguanil in these individuals (245, 534 and 552 ml min-1) compared with the rest of the population (858 +/- 482 ml min-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ml] / [min],534,146244,DB01131,Proguanil
,2291871,oral clearance,"2. Pharmacokinetic analysis showed that this observation resulted from a reduced oral clearance of proguanil in these individuals (245, 534 and 552 ml min-1) compared with the rest of the population (858 +/- 482 ml min-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ml] / [min],552,146245,DB01131,Proguanil
,2291871,oral clearance,"2. Pharmacokinetic analysis showed that this observation resulted from a reduced oral clearance of proguanil in these individuals (245, 534 and 552 ml min-1) compared with the rest of the population (858 +/- 482 ml min-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ml] / [min],858,146246,DB01131,Proguanil
,2291871,Peak plasma concentrations,"3. Peak plasma concentrations of active metabolite were significantly lower in these subjects (54.2, 26.8 and 51.7 ng ml-1) compared with the rest of the population (141 +/- 45.2 ng ml-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ng] / [ml],54.2,146247,DB01131,Proguanil
,2291871,Peak plasma concentrations,"3. Peak plasma concentrations of active metabolite were significantly lower in these subjects (54.2, 26.8 and 51.7 ng ml-1) compared with the rest of the population (141 +/- 45.2 ng ml-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ng] / [ml],26.8,146248,DB01131,Proguanil
,2291871,Peak plasma concentrations,"3. Peak plasma concentrations of active metabolite were significantly lower in these subjects (54.2, 26.8 and 51.7 ng ml-1) compared with the rest of the population (141 +/- 45.2 ng ml-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ng] / [ml],51.7,146249,DB01131,Proguanil
,2291871,Peak plasma concentrations,"3. Peak plasma concentrations of active metabolite were significantly lower in these subjects (54.2, 26.8 and 51.7 ng ml-1) compared with the rest of the population (141 +/- 45.2 ng ml-1).",The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291871/),[ng] / [ml],141,146250,DB01131,Proguanil
,9764334,Para,"Parasite and fever clearance times were 47 h (range 8-75) and 50 h (range 7-111), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,47,165773,DB01131,Proguanil
,9764334,clearance times,"Parasite and fever clearance times were 47 h (range 8-75) and 50 h (range 7-111), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,50,165774,DB01131,Proguanil
,9764334,time to peak concentrations,"Atovaquone and proguanil were rapidly absorbed, with median time to peak concentrations of 6 h (range 6-24) and 6 h (range 6-12), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,6,165775,DB01131,Proguanil
,9764334,time to peak concentrations,"Atovaquone and proguanil were rapidly absorbed, with median time to peak concentrations of 6 h (range 6-24) and 6 h (range 6-12), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,6,165776,DB01131,Proguanil
,9764334,peak plasma concentration,Mean peak plasma concentration of atovaquone on day 3 was 5.1 micrograms/mL (SD = 2.1).,Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[μg] / [ml],5.1,165777,DB01131,Proguanil
,9764334,peak plasma concentration,The day 3 mean peak plasma concentration of proguanil was 306 ng/mL (SD = 108) compared with 44.3 ng/mL (SD = 27.3) for cycloguanil.,Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [ml],306,165778,DB01131,Proguanil
,9764334,peak plasma concentration,The day 3 mean peak plasma concentration of proguanil was 306 ng/mL (SD = 108) compared with 44.3 ng/mL (SD = 27.3) for cycloguanil.,Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [ml],44.3,165779,DB01131,Proguanil
,9764334,AUC (area under plasma concentration-time curve),"Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[μg] / [h·ml],161.8,165780,DB01131,Proguanil
,9764334,AUC (area under plasma concentration-time curve),"Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [h·ml],4646,165781,DB01131,Proguanil
,9764334,AUC (area under plasma concentration-time curve),"Mean values for the AUC (area under plasma concentration-time curve) were 161.8 micrograms/mL.h (SD = 126.9) for atovaquone, 4646 ng/mL.h (SD = 1226) for proguanil, and 787 ng/mL.h (SD = 397) for cycloguanil.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),[ng] / [h·ml],787,165782,DB01131,Proguanil
,9764334,Terminal elimination half-lives,"Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,31.8,165783,DB01131,Proguanil
,9764334,Terminal elimination half-lives,"Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,14.9,165784,DB01131,Proguanil
,9764334,Terminal elimination half-lives,"Terminal elimination half-lives of atovaquone, proguanil and cycloguanil were estimated as 31.8 h (SD = 8.9), 14.9 h (SD = 3.3) and 14.6 h (SD = 2.6), respectively.",Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9764334/),h,14.6,165785,DB01131,Proguanil
,9180597,plasma clearances,"The mean plasma clearances of proguanil for EMs and PMs were 1.31 and 1.10 L/hr/kg, respectively.",Disposition of proguanil in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180597/),[l] / [h·kg],1.31,181167,DB01131,Proguanil
,9180597,plasma clearances,"The mean plasma clearances of proguanil for EMs and PMs were 1.31 and 1.10 L/hr/kg, respectively.",Disposition of proguanil in Thai patients with uncomplicated falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180597/),[l] / [h·kg],1.10,181168,DB01131,Proguanil
,9180597,elimination half-life,The mean elimination half-life of proguanil was statistically longer in PMs than EMs (19.6 hr versus 16.1 hr; P = 0.01).,Disposition of proguanil in Thai patients with uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180597/),h,19.6,181169,DB01131,Proguanil
,9180597,elimination half-life,The mean elimination half-life of proguanil was statistically longer in PMs than EMs (19.6 hr versus 16.1 hr; P = 0.01).,Disposition of proguanil in Thai patients with uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9180597/),h,16.1,181170,DB01131,Proguanil
,21612571,fluxes,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],12.89,181642,DB01131,Proguanil
,21612571,fluxes,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],5.88,181643,DB01131,Proguanil
,21612571,plasma concentrations,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [ml],1.4,181644,DB01131,Proguanil
,21612571,plasma concentrations,"From the first study, mean fluxes for AT and PR were 12.89 ± 1.2 and 5.88 ± 0.9 µg cm(-2) h(-1) respectively; pharmacokinetic calculations indicated that these fluxes were insufficient to achieve the target plasma concentrations for AT and PR of 1.4 µg mL(-1) and 200 ng mL(-1) respectively, in the treatment of falciparum malaria.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[ng] / [ml],200,181645,DB01131,Proguanil
,21612571,fluxes,"However, in the second study, the fluxes of AT and PR increased to 50.92 ± 20.8 and 12.01 ± 1.5 µg cm(-2) h(-1) respectively, and pharmacokinetic calculations indicated that therapeutic plasma concentrations are attainable for pediatric application.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],50.92,181646,DB01131,Proguanil
,21612571,fluxes,"However, in the second study, the fluxes of AT and PR increased to 50.92 ± 20.8 and 12.01 ± 1.5 µg cm(-2) h(-1) respectively, and pharmacokinetic calculations indicated that therapeutic plasma concentrations are attainable for pediatric application.","Delivery of atovaquone and proguanil across sublingual membranes, in vitro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21612571/),[μg] / [(cm)^2·h],12.01,181647,DB01131,Proguanil
,25047305,elimination half-lives,"AS and DHA showed mean elimination half-lives of 0.17 hours and 1.30 hours, respectively.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),h,0.17,188992,DB01131,Proguanil
,25047305,elimination half-lives,"AS and DHA showed mean elimination half-lives of 0.17 hours and 1.30 hours, respectively.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),h,1.30,188993,DB01131,Proguanil
,25047305,peak concentration (Cmax),"The high mean peak concentration (Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"28,558",188994,DB01131,Proguanil
,25047305,Cmax,"The high mean peak concentration (Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"2,932",188995,DB01131,Proguanil
,25047305,Cmax,"For example, Cmax values of AS were calculated to range from 3,362 to 55,873 ng/mL, and the Cmax value of DHA was noted to vary from 1,493 to 5,569 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"3,362 to 55,873",188996,DB01131,Proguanil
,25047305,Cmax,"For example, Cmax values of AS were calculated to range from 3,362 to 55,873 ng/mL, and the Cmax value of DHA was noted to vary from 1,493 to 5,569 ng/mL.",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[ng] / [ml],"1,493 to 5,569",188997,DB01131,Proguanil
,25047305,area under the curve (AUC),"The mean area under the curve (AUC) of AS was shown to be approximately half that of DHA (1,878 ng · h/mL vs 3,543 ng · h/mL).",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[h·ng] / [ml],"1,878",188998,DB01131,Proguanil
,25047305,area under the curve (AUC),"The mean area under the curve (AUC) of AS was shown to be approximately half that of DHA (1,878 ng · h/mL vs 3,543 ng · h/mL).",Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25047305/),[h·ng] / [ml],"3,543",188999,DB01131,Proguanil
,12556158,plasma half-lives,"Published pharmacokinetic data indicate that after treatment of patients with therapeutic doses of atovaquone/proguanil hydrochloride (Malarone, GlaxoSmithKline Research Triangle Park, NC), the plasma half-lives of these drugs are 70h and 15h, respectively.",Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12556158/),h,70,210620,DB01131,Proguanil
,12556158,plasma half-lives,"Published pharmacokinetic data indicate that after treatment of patients with therapeutic doses of atovaquone/proguanil hydrochloride (Malarone, GlaxoSmithKline Research Triangle Park, NC), the plasma half-lives of these drugs are 70h and 15h, respectively.",Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12556158/),h,15,210621,DB01131,Proguanil
,12472986,maximum excretion rate [(dDu/dt)max],"The mean maximum excretion rate [(dDu/dt)max] of Clox when taken alone was 16.13 +/- 2.92 mg/h at tmax of 1.86 +/- 01.07 hours, whereas in the presence of PG, it was 7.72 +/- 3.24 mg/h at tmax of 2.43 +/- 00.98 hours (P < 0.0001).",Effect of proguanil interaction on bioavailability of cloxacillin. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472986/),[mg] / [h],16.13,222354,DB01131,Proguanil
,12472986,tmax,"The mean maximum excretion rate [(dDu/dt)max] of Clox when taken alone was 16.13 +/- 2.92 mg/h at tmax of 1.86 +/- 01.07 hours, whereas in the presence of PG, it was 7.72 +/- 3.24 mg/h at tmax of 2.43 +/- 00.98 hours (P < 0.0001).",Effect of proguanil interaction on bioavailability of cloxacillin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472986/),h,1.86,222355,DB01131,Proguanil
,12472986,tmax,"The mean maximum excretion rate [(dDu/dt)max] of Clox when taken alone was 16.13 +/- 2.92 mg/h at tmax of 1.86 +/- 01.07 hours, whereas in the presence of PG, it was 7.72 +/- 3.24 mg/h at tmax of 2.43 +/- 00.98 hours (P < 0.0001).",Effect of proguanil interaction on bioavailability of cloxacillin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472986/),[mg] / [h],7.72,222356,DB01131,Proguanil
,12472986,tmax,"The mean maximum excretion rate [(dDu/dt)max] of Clox when taken alone was 16.13 +/- 2.92 mg/h at tmax of 1.86 +/- 01.07 hours, whereas in the presence of PG, it was 7.72 +/- 3.24 mg/h at tmax of 2.43 +/- 00.98 hours (P < 0.0001).",Effect of proguanil interaction on bioavailability of cloxacillin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472986/),h,2.43,222357,DB01131,Proguanil
,12472986,Du infinity,The total amount of Clox excreted in urine (Du infinity) in 12 h was markedly reduced by coadministration with PG by up to 48% with Du infinity of 49.57 +/- 8.16 mg after Clox alone and 25.81 +/- 8.46 mg in the presence of PG (P < 0.0001).,Effect of proguanil interaction on bioavailability of cloxacillin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472986/),mg,49.57,222358,DB01131,Proguanil
,12472986,Du infinity,The total amount of Clox excreted in urine (Du infinity) in 12 h was markedly reduced by coadministration with PG by up to 48% with Du infinity of 49.57 +/- 8.16 mg after Clox alone and 25.81 +/- 8.46 mg in the presence of PG (P < 0.0001).,Effect of proguanil interaction on bioavailability of cloxacillin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12472986/),mg,25.81,222359,DB01131,Proguanil
,10492061,maximum plasma concentrations,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[μg] / [ml],13.02,237891,DB01131,Proguanil
,10492061,maximum plasma concentrations,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[ng] / [ml],742,237892,DB01131,Proguanil
,10492061,elimination half-lives,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),h,42.2,237893,DB01131,Proguanil
,10492061,elimination half-lives,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),h,14.4,237894,DB01131,Proguanil
,10492061,oral plasma clearance,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[ml] / [h·kg],90,237895,DB01131,Proguanil
,10492061,oral plasma clearance,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[ml] / [h·kg],710,237896,DB01131,Proguanil
,10492061,apparent volumes of distribution,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[1] / [kg],4.9,237897,DB01131,Proguanil
,10492061,apparent volumes of distribution,"Artesunate did not alter the pharmacokinetic properties of atovaquone and proguanil (maximum plasma concentrations: 13.02 microg/ml and 742 ng/ml; elimination half-lives: 42.2 h and 14.4 h; oral plasma clearance estimates: 90 ml/h/kg and 710 ml/h/kg; and apparent volumes of distribution: 4.9 1/kg and 14.5 1/kg, respectively).",Absence of an interaction between artesunate and atovaquone--proguanil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492061/),[1] / [kg],14.5,237898,DB01131,Proguanil
,19761366,area under the concentration versus curve at 24 h (AUC(0-24)),Participants with the CYP2C19*17 allele had higher chlorcycloguanil area under the concentration versus curve at 24 h (AUC(0-24)) than those without (geometric means: 317 vs 216 ng.h/ml; ratio of geometric means: 1.46; 95% CI: 1.03 to 2.09; p = 0.0363) and higher C(max) (geometric mean ratio: 1.52; 95% CI: 1.13 to 2.05; p = 0.0071).,Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761366/),[h·ng] / [ml],317,238282,DB01131,Proguanil
,19761366,area under the concentration versus curve at 24 h (AUC(0-24)),Participants with the CYP2C19*17 allele had higher chlorcycloguanil area under the concentration versus curve at 24 h (AUC(0-24)) than those without (geometric means: 317 vs 216 ng.h/ml; ratio of geometric means: 1.46; 95% CI: 1.03 to 2.09; p = 0.0363) and higher C(max) (geometric mean ratio: 1.52; 95% CI: 1.13 to 2.05; p = 0.0071).,Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761366/),[h·ng] / [ml],216,238283,DB01131,Proguanil
,10424325,area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h),The geometric mean of the area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h) was 180 microg x ml(-1) h following administration of atovaquone alone and 193 microg x ml(-1) h following atovaquone with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·μg] / [ml],180,246433,DB01131,Proguanil
,10424325,area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h),The geometric mean of the area under the atovaquone plasma concentration-time curve calculated from 0 to 24 h after the last dose (AUC0->24h) was 180 microg x ml(-1) h following administration of atovaquone alone and 193 microg x ml(-1) h following atovaquone with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·μg] / [ml],193,246434,DB01131,Proguanil
,10424325,AUC0->24h,The geometric mean AUC0->24h for proguanil was 6296 ng x ml(-1) x h after proguanil alone and 5819 ng x ml(-1) x h following proguanil with atovaquone.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·ng] / [ml],6296,246435,DB01131,Proguanil
,10424325,AUC0->24h,The geometric mean AUC0->24h for proguanil was 6296 ng x ml(-1) x h after proguanil alone and 5819 ng x ml(-1) x h following proguanil with atovaquone.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),[h·ng] / [ml],5819,246436,DB01131,Proguanil
,10424325,elimination half-life (t1/2),The geometric mean elimination half-life (t1/2) of atovaquone was 57.1 h when given alone and 59.0 h when administered together with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,57.1,246437,DB01131,Proguanil
,10424325,elimination half-life (t1/2),The geometric mean elimination half-life (t1/2) of atovaquone was 57.1 h when given alone and 59.0 h when administered together with proguanil.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,59.0,246438,DB01131,Proguanil
,10424325,t1/2,The corresponding geometric mean values of t1/2 for proguanil were 13.7 h and 14.5 h.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,13.7,246439,DB01131,Proguanil
,10424325,t1/2,The corresponding geometric mean values of t1/2 for proguanil were 13.7 h and 14.5 h.,Lack of a pharmacokinetic interaction between atovaquone and proguanil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424325/),h,14.5,246440,DB01131,Proguanil
,2884288,rate constants of elimination,A single compartment model is applicable for cycloguanil with mean rate constants of elimination of 0.0624 h-1 and availability of 0.2398 h-1.,"A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884288/),1/[h],0.0624,250364,DB01131,Proguanil
,2884288,availability,A single compartment model is applicable for cycloguanil with mean rate constants of elimination of 0.0624 h-1 and availability of 0.2398 h-1.,"A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2884288/),1/[h],0.2398,250365,DB01131,Proguanil
,19961932,C(max),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),[mg] / [l],2.55,256798,DB01131,Proguanil
,19961932,C(max),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),[mg] / [l],3.75,256799,DB01131,Proguanil
,19961932,T(max),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),h,2.80,256800,DB01131,Proguanil
,19961932,T(max),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),h,4.80,256801,DB01131,Proguanil
,19961932,AUC(T),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),[mgh] / [l],45.58,256802,DB01131,Proguanil
,19961932,AUC(T),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),[mgh] / [l],97.00,256803,DB01131,Proguanil
,19961932,T(1/2beta),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),h,16.50,256804,DB01131,Proguanil
,19961932,T(1/2beta),"Co-administration of proguanil and efavirenz resulted in significant increases (p < 0.05) in C(max), T(max), AUC(T) and elimination half-life (T(1/2beta)) of proguanil compared with values for proguanil alone [C(max): 2.55+/-0.24 mg/l vs 3.75+/-0.48 mg/l; T(max): 2.80+/-0.99 h vs 4.80+/-0.99 h; AUC(T): 45.58+/-12.75 mgh/l vs 97.00+/-23.33 mgh/l; T(1/2beta): 16.50+/-4.55 h vs 23.24+/-4.08 h].",Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19961932/),h,23.24,256805,DB01131,Proguanil
,12659609,maximum serum concentration,Pharmacokinetic modeling suggested that the patient's initial over-treatment was as reported and that the predicted maximum serum concentration of chloroquine (902 micro g/L) was within the range seen in fatal chloroquine overdose.,Toxicity related to chloroquine treatment of resistant vivax malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659609/),[μg] / [l],902,256908,DB01131,Proguanil
less,26969110,solubility,"However, Atovaquone is a highly lipophilic drug having poor aqueous solubility (less than 0.2 μg/ml) thus reducing its oral bioavailability.",Bioavailability enhancement of atovaquone using hot melt extrusion technology. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26969110/),[μg] / [ml],0.2,259354,DB01131,Proguanil
,16552504,oral clearance (CI/F),"For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h.",Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16552504/),[l] / [hour·kg],4.0,259475,DB01131,Proguanil
,16552504,total apparent volume of distribution (Vd/f),"For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h.",Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16552504/),[l] / [kg],3.4,259476,DB01131,Proguanil
,16552504,terminal elimination half-life,"For DHA the median [90% range] estimate of oral clearance (CI/F) was 4.0 [0.8-20.7] l hour(-1) kg(-1), total apparent volume of distribution (Vd/f) was 3.4 [0.9-60.7] l/kg, and terminal elimination half-life was 1.0 [0.6-2.4] h.",Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16552504/),h,1.0,259477,DB01131,Proguanil
less,21914160,half-life,"Intravenous AS is associated with high initial AS concentrations which subsequently decline rapidly, with typical AS half-life estimates of less than 15 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,15,260913,DB01131,Proguanil
,21914160,clearance,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],2 - 3,260914,DB01131,Proguanil
,21914160,volume,"AS clearance and volume estimates average 2 - 3 L/kg/hr and 0.1 - 0.3 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.1 - 0.3,260915,DB01131,Proguanil
,21914160,half-life,"DHA concentrations peak within 25 minutes post-dose, and DHA is eliminated with a half-life of 30 - 60 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,30 - 60,260916,DB01131,Proguanil
,21914160,clearance,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [h·kg],0.5 - 1.5,260917,DB01131,Proguanil
,21914160,volume,"DHA clearance and volume average between 0.5 - 1.5 L/kg/hr and 0.5 - 1.0 L/kg, respectively.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),[l] / [kg],0.5 - 1.0,260918,DB01131,Proguanil
>,21914160,bioavailability,"Compared to IV administration, IM administration produces lower peaks, longer half-life values, and higher volumes of distribution for AS, as well as delayed peaks for DHA; other parameters are generally similar due to the high bioavailability, assessed by exposure to DHA, associated with IM AS administration (> 86%).","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,86,260919,DB01131,Proguanil
>,21914160,bioavailability,Similarly high bioavailability of DHA (> 80%) is associated with oral administration.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),%,80,260920,DB01131,Proguanil
,21914160,half-life,"Following oral AS, peak AS concentrations (Cmax) are achieved within one hour, and AS is eliminated with a half-life of 20 - 45 minutes.","Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),min,20 - 45,260921,DB01131,Proguanil
,21914160,half-life,DHA Cmax values are observed within two hours post-dose; DHA half-life values average 0.5 - 1.5 hours.,"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21914160/),h,0.5 - 1.5,260922,DB01131,Proguanil
higher,16310420,extraction efficiency,"The extraction efficiency of PG, CG and 4CPB from rat blood and plasma was higher than 73%.",Sensitive method for the quantitative determination of proguanil and its metabolites in rat blood and plasma by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16310420/),%,73,264713,DB01131,Proguanil
,7619672,elimination half-life (t 1/2),2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),h,20.6,264839,DB01131,Proguanil
,7619672,elimination half-life (t 1/2),2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),h,14.6,264840,DB01131,Proguanil
,7619672,AUC,2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),h,14.6,264841,DB01131,Proguanil
,7619672,AUC,2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],5.43,264842,DB01131,Proguanil
,7619672,AUC,2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h).,Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],3.68,264843,DB01131,Proguanil
,7619672,"AUC(0,24 h)","Mean AUC(0,24 h) values of CPB were significantly (P < 0.05) lower in the PM (n = 4) than in the EM group (n = 14) (0.47 +/- 0.13 vs 0.88 +/- 0.50 (-0.14 to 0.96) micrograms ml-1 h).",Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],0.47,264844,DB01131,Proguanil
,7619672,"AUC(0,24 h)","Mean AUC(0,24 h) values of CPB were significantly (P < 0.05) lower in the PM (n = 4) than in the EM group (n = 14) (0.47 +/- 0.13 vs 0.88 +/- 0.50 (-0.14 to 0.96) micrograms ml-1 h).",Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619672/),[h·μg] / [ml],0.88,264845,DB01131,Proguanil
,8491239,peak plasma concentrations,Median peak plasma concentrations of proguanil during pregnancy and following delivery were 212 and 215 ng.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),ng,212,265332,DB01131,Proguanil
,8491239,peak plasma concentrations,Median peak plasma concentrations of proguanil during pregnancy and following delivery were 212 and 215 ng.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),ng,215,265333,DB01131,Proguanil
,8491239,plasma AUC,"Mean plasma AUC values for proguanil during and following pregnancy were 94 and 98 ng.h.ml-1.kg-1, respectively.",Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),[h·ng] / [kg·ml],94,265334,DB01131,Proguanil
,8491239,plasma AUC,"Mean plasma AUC values for proguanil during and following pregnancy were 94 and 98 ng.h.ml-1.kg-1, respectively.",Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),[h·ng] / [kg·ml],98,265335,DB01131,Proguanil
,8491239,AUC,Corresponding whole blood AUC values were 361 and 396 ng.h.ml-1.kg-1.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),[h·ng] / [kg·ml],361,265336,DB01131,Proguanil
,8491239,AUC,Corresponding whole blood AUC values were 361 and 396 ng.h.ml-1.kg-1.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),[h·ng] / [kg·ml],396,265337,DB01131,Proguanil
,8491239,elimination half lives,The mean elimination half lives and mean residence times of proguanil in plasma and whole blood were 12.3 and 19.6 h and 13.8 and 20.7 h respectively during pregnancy.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),h,12.3,265338,DB01131,Proguanil
,8491239,mean residence times,The mean elimination half lives and mean residence times of proguanil in plasma and whole blood were 12.3 and 19.6 h and 13.8 and 20.7 h respectively during pregnancy.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),h,19.6,265339,DB01131,Proguanil
,8491239,mean residence times,The mean elimination half lives and mean residence times of proguanil in plasma and whole blood were 12.3 and 19.6 h and 13.8 and 20.7 h respectively during pregnancy.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),h,13.8,265340,DB01131,Proguanil
,8491239,mean residence times,The mean elimination half lives and mean residence times of proguanil in plasma and whole blood were 12.3 and 19.6 h and 13.8 and 20.7 h respectively during pregnancy.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),h,20.7,265341,DB01131,Proguanil
,8491239,peak plasma,Mean peak plasma and whole blood concentrations of cycloguanil following pregnancy were 25 and 22 ng.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),ng,25,265342,DB01131,Proguanil
,8491239,whole blood concentrations,Mean peak plasma and whole blood concentrations of cycloguanil following pregnancy were 25 and 22 ng.,Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),ng,22,265343,DB01131,Proguanil
,8491239,peak cycloguanil concentrations,"During pregnancy peak cycloguanil concentrations in both plasma and whole blood were markedly lower, 13 and 12 ng ml-1, respectively.",Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),[ng] / [ml],13,265344,DB01131,Proguanil
,8491239,peak cycloguanil concentrations,"During pregnancy peak cycloguanil concentrations in both plasma and whole blood were markedly lower, 13 and 12 ng ml-1, respectively.",Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),[ng] / [ml],12,265345,DB01131,Proguanil
,8491239,ratio of progua,"The mean ratio of proguanil to cycloguanil plasma AUC was 16.7 in the third trimester of pregnancy and 7.8 following pregnancy, compared with less than 5 in previously reported studies.",Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),,16.7,265346,DB01131,Proguanil
,8491239,ratio of progua,"The mean ratio of proguanil to cycloguanil plasma AUC was 16.7 in the third trimester of pregnancy and 7.8 following pregnancy, compared with less than 5 in previously reported studies.",Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),,7.8,265347,DB01131,Proguanil
less,8491239,ratio of progua,"The mean ratio of proguanil to cycloguanil plasma AUC was 16.7 in the third trimester of pregnancy and 7.8 following pregnancy, compared with less than 5 in previously reported studies.",Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491239/),,5,265348,DB01131,Proguanil
